News

Patient Perspectives from the FDA Public Meeting: the Impact of Rare Diseases
I recently had the opportunity to attend this public meeting at the FDA to discuss the Patient Perspectives on the Impact of Rare Diseases. This meeting was held as opportunity to bring the voices of patients and caregivers to the...
Read More
Advancing Amyloidosis: Roadmap for Research
FOR IMMEDIATE RELEASE LEADING EXPERTS PUBLISH A ROADMAP FOR CRITICAL AREAS OF RESEARCH IN AMYLOIDOSIS (more…)
Read More
ARC’s Advocates work Capitol Hill
Our ARC team of amyloidosis patients, caregivers and ARC staff took part as advocates in key activities during the week of Rare Disease Day, which is held on February 28th each year.  (more…)
Read More
Join us for Rare Disease Week: Act Now!
Rare disease day takes place on February 28th of each year. The entire week provides a unique opportunity to advocate and raise awareness of key policy issues that affect amyloidosis patients. (more…)
Read More
Tafamidis under review
Tafamidis accepted for FDA Review in 2019
Earlier this month, Pfizer announced that it has made two separate FDA submissions for their drug tafamidis, based on evidence generated from the Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) clinical trial, (more…)
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization